Epoetin alfa

Common Uses

Epoetin alfa is primarily used to stimulate the production of red blood cells in people with specific medical conditions that cause anemia. These conditions include:

• Chronic Kidney Disease: It is used for patients with kidney failure, whether or not they are on dialysis, to manage anemia and reduce the need for blood transfusions.
• Cancer Chemotherapy: It is used to treat anemia in patients with certain types of cancer (non-myeloid) who are receiving chemotherapy that suppresses the bone marrow's ability to make red blood cells.
• HIV Treatment: It is used for patients with HIV who are taking zidovudine (AZT) and have developed anemia as a side effect of the medication.

Use in Surgery

Epoetin alfa may be used before certain elective, non-cardiac, and non-vascular surgeries. In these cases, the goal is to increase red blood cell levels before the procedure to decrease the likelihood that the patient will require a blood transfusion from a donor.

Stimulating Red Blood Cell Production

Epoetin alfa belongs to a class of medications known as erythropoiesis-stimulating agents (ESAs). It functions similarly to erythropoietin, a hormone naturally produced by the kidneys that tells the body when to make more red blood cells.

The medication works through the following process:

• Targeting the bone marrow: After the medication is injected, it travels to the bone marrow, which is the soft tissue inside the bones responsible for creating blood cells.
• Triggering cell growth: It stimulates the division and survival of the cells in the bone marrow that eventually become mature red blood cells.
• Increasing oxygen capacity: Red blood cells contain hemoglobin, which is necessary for carrying oxygen from the lungs to the rest of the body. By increasing the number of red blood cells, the medication helps correct anemia and improves the body's ability to transport oxygen.

In individuals with chronic kidney disease, the kidneys may not produce enough natural erythropoietin. Similarly, certain medical treatments like chemotherapy or specific medications can interfere with the body's ability to maintain adequate red blood cell levels. Epoetin alfa acts as a replacement for the missing natural hormone to help maintain a healthy red blood cell count and reduce the need for blood transfusions.

Common Side Effects

• Fever, cough, or sore throat
• Headache
• Joint, muscle, or bone pain
• Nausea, vomiting, or diarrhea
• Mouth sores
• Itching or skin rash
• Trouble sleeping
• Pain, redness, or swelling at the injection site

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Signs of high blood pressure, such as severe headache, blurred vision, or pounding in your neck or ears
• Signs of a blood clot, including pain, swelling, or warmth in an arm or leg
• Chest pain or shortness of breath
• Sudden confusion, trouble speaking, or weakness on one side of the body
• Seizures
• Severe skin reactions, including blistering, peeling, or red skin rashes
• Extreme tiredness, pale skin, or fainting
• Rapid weight gain or swelling in the hands or feet

Boxed Warning: Serious Cardiovascular and Tumor Risks

Epoetin alfa carries a boxed warning due to the risk of serious and potentially life-threatening events. These include:

• Cardiovascular Events: Increased risk of death, heart attack, stroke, and blood clots (thromboembolism). These risks are higher when the medication is used to target a hemoglobin level of 11 g/dL or higher.
• Cancer Progression: In patients with certain types of cancer (including breast, lung, head and neck, lymphoid, and cervical cancers), erythropoiesis-stimulating agents (ESAs) like epoetin alfa may cause tumors to grow faster or result in earlier death.
• Surgery Risks: Patients undergoing major surgery have an increased risk of deep vein thrombosis (DVT) when taking this medication, particularly if they are not receiving blood-thinning treatment.

Contraindications

Epoetin alfa is not recommended for individuals with certain conditions, including:

• Uncontrolled high blood pressure (hypertension).
• Pure red cell aplasia (PRCA) that begins after treatment with any erythropoietin protein.
• A history of serious allergic reactions to epoetin alfa or any of its ingredients.

Additional Precautions

Hypertension

Blood pressure may increase or become difficult to control during treatment. Blood pressure monitoring is necessary, and medications to manage hypertension may need to be started or adjusted. If blood pressure cannot be controlled, epoetin alfa may need to be reduced or discontinued.

Seizures

There is an increased risk of seizures, particularly during the first 90 days of treatment. Patients are often advised to avoid potentially hazardous activities, such as driving or operating heavy machinery, during this initial period.

Pure Red Cell Aplasia (PRCA)

In rare cases, the body may develop antibodies against the medication, leading to a condition called pure red cell aplasia. This causes severe anemia and a sudden loss of response to the drug. If PRCA is suspected, the medication must be permanently discontinued.

Serious Skin Reactions

Life-threatening skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported. Treatment should be stopped immediately if a severe rash or skin peeling occurs.

Pregnancy

There is limited research on the safety of epoetin alfa in pregnant women. Animal studies have indicated that high doses may lead to decreased fetal body weight or bone development issues, but it is unclear if these risks apply to human pregnancies. This medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Certain multi-dose vials of epoetin alfa contain benzyl alcohol as a preservative. While the risk to a fetus from a mother receiving these injections is considered low, benzyl alcohol is known to cause serious complications in premature infants if they are exposed directly. Patients should discuss the specific formulation of their medication with a healthcare provider.

Breastfeeding

It is not known if epoetin alfa is excreted in human breast milk. Because the effects on a nursing infant are unknown, healthcare providers recommend exercising caution when administering this drug to someone who is breastfeeding. It is important to discuss feeding options and potential risks with a doctor before starting treatment.

Available Forms

Epoetin alfa is supplied as a clear, colorless liquid solution for injection. It is available in two primary vial types:

• Single-dose vials: These are preservative-free and intended for one-time use. Any unused portion remaining in the vial must be discarded.
• Multiple-dose vials: These contain a preservative (benzyl alcohol) and are designed to be used for more than one dose.

Strengths

The medication is available in various concentrations measured in Units per milliliter (Units/mL). Common strengths include:

• 2,000 Units/mL
• 3,000 Units/mL
• 4,000 Units/mL
• 10,000 Units/mL
• 20,000 Units/mL
• 40,000 Units/mL

The specific strength and dosage prescribed depend on the patient's condition, body weight, and hemoglobin response.

Administration

Epoetin alfa is administered by injection using two main methods:

• Subcutaneous injection: The medication is injected into the fatty tissue just under the skin, typically in the thigh or abdomen.
• Intravenous (IV) injection: The medication is injected directly into a vein or into the venous port of a dialysis machine for patients undergoing treatment for kidney disease.

FDA Approval and Indications

Epoetin alfa is approved by the U.S. Food and Drug Administration (FDA) for the treatment of anemia caused by several specific conditions:

• Chronic kidney disease (CKD) in patients on dialysis and those not on dialysis.
• Zidovudine therapy in patients with HIV.
• The effects of myelosuppressive chemotherapy in patients with non-myeloid malignancies, specifically when the treatment is not intended to be curative.
• Reduction of the need for red blood cell transfusions in patients scheduled for elective, noncardiac, nonvascular surgery.

Boxed Warning

The FDA requires a Boxed Warning for epoetin alfa because it increases the risk of serious cardiovascular events, including death, myocardial infarction (heart attack), stroke, and venous thromboembolism. These risks are higher when the medication is used to target a hemoglobin level of 11 g/dL or higher.

In patients with certain types of cancer, the medication may also result in shortened overall survival or an increased risk of tumor progression or recurrence. Because of these risks, it is only indicated for chemotherapy-induced anemia when the goal of treatment is not a cure.

Regulatory History and REMS

In 2017, the FDA determined that the Risk Evaluation and Mitigation Strategy (REMS) program, previously known as the ESA APPRISE program, was no longer necessary. The agency concluded that the risks were well-understood by the medical community and could be managed through professional labeling and current prescribing information. However, the serious safety risks remain documented in the medication's Boxed Warning, and healthcare providers are advised to use the lowest dose necessary to avoid red blood cell transfusions.

Factors Influencing Cost

Several factors determine the total cost of treatment with epoetin alfa:

• Dosage and Frequency: Higher doses or more frequent injections will increase the overall price.
• Biosimilars: Epoetin alfa is available as a biosimilar. Biosimilars are highly similar to the original biologic drug and are often available at a lower cost.
• Administration Setting: The cost may differ depending on whether the medication is administered in a hospital, a dialysis center, or at home.

Insurance and Coverage

Most insurance plans, including Medicare and Medicaid, provide coverage for epoetin alfa when it is used for approved conditions such as anemia related to chronic kidney disease or chemotherapy. However, insurance companies often require prior authorization, which means a healthcare provider must justify the medical necessity of the drug before the plan will pay for it.

Financial Assistance

For patients without insurance or those with high out-of-pocket costs, financial assistance programs may be available. These programs are often provided by drug manufacturers or non-profit organizations to help cover the cost of the medication.